GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

GeneDx Holdings Corp. Class A Common Stock

GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale.

Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of Centrellis®, our innovative health information platform. Powered by millions of medical records, Centrellis® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data.

As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by Centrellis®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery.

Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.

GeneDx

Congratulations to Akouos on the news of their investigational #gene therapy treatment for otoferlin gene (OTOF)-mediated hearing loss, a rare congenital deafness impacting roughly 200,000 people worldwide. GeneDx is proud to partner with Akouos to help accelerate enrollment in #clinicaltrials by leveraging our robust dataset to identify other #patients who can benefit from these #therapies. We’re humbled to be part of the ecosystem of #healthcare innovation and improving access to pioneering treatments for more patients. 

https://nyti.ms/3OlRYAK

9 state #Medicaid programs now cover rapid whole #genome #sequencing (rWGS) in the #pediatric inpatient setting.  

Utah joins a growing list of states who recognize the importance of offering rWGS in the #NICU and PICU to provide a rapid #diagnosis for the most vulnerable patients and their families.

Couldn’t be prouder of the entire team at GeneDx on an outstanding fourth quarter. Our preliminary results put us ahead on revenue and cash burn goals. We’re proving that we can work together as a team committed to our patients, our providers, our partners, and to our shareholders. 2024 is already off to a strong start. Thank you to everyone for helping keep our eyes on the goal of diagnosing inherited disease earlier, connecting people with the right treatment, and driving a healthier future for as many families as possible.
https://lnkd.in/eHQUhcK8

Harness deep #genomic data. Provide more definitive #answers. Deliver improved outcomes. With one of the world’s largest #raredisease clinical data sets, GeneDx can help you bring #precision medicine into your practice. Our vision is big: leverage tomorrow’s technology to improve patients’ lives, today.

Uncertainty and delayed diagnoses are too common among patients with #neurodevelopmental disorders (NDDs). That’s why leading medical societies recognize #exome or #genome #sequencing as the best, first-tier #genetic testing option. 

For a child with NDDs, every day without a genetic #diagnosis is a missed opportunity. With GeneDx exome testing, you can provide more timely, cost-effective, and comprehensive clinical evaluations that deliver actionable insights. 

Choose a comprehensive and cost-effective genetic testing option supported by leading medical societies.

There’s no place like home for the #holidays. But for the most vulnerable #patients and their families, this isn’t always a possibility. Give them the gift of #genetic insights that can help inform #diagnosis, direct #treatment, and make sure they’re back where they belong: in the arms of their loved ones.

Five. That’s how many uninformative tests the average child with #neurodevelopmental disorders undergoes in search of a #genetic diagnosis. Find critical information sooner by ordering GeneDx #exome first. Test once, discover more, and help your #patients get the care they need #earlier.

Incorporating comprehensive #genomic #sequencing into your workflow doesn’t have to be complicated. Instead, let us do the heavy lifting. We can assist with: 
✅ selecting appropriate tests 
✅ answering #clinical questions 
✅ reporting patient-centric #results 
✅ guiding potential next steps 
 
With comprehensive care from start to finish, GeneDx offers more than a test result: we deliver actionable insights that promote optimal #health.

Are you a #healthcare provider working in a #NICU? Do you want to implement rapid #GeneticTesting, but lack genetic specialist support?

Learn how to interpret #genetic results & discuss them with caregivers, with insights from a panel of experts. 

Click here, watch at your convenience & earn 1 #CME credit 👉 https://bit.ly/47lLd9N

What more can you do for your patients in the #NICU? Rapid whole #genome sequencing (rWGS) might be the answer. It’s been shown to: 
✅ Change clinical management in 61% of patients 
✅ Reduce the length of NICU stays by >457 days 
✅ Reduce #healthcare costs by $12K-16K per #patient 
 
Learn more about the power of #rWGS by visiting the GeneDx team at the Nemours Children's #Neonatology Conference in Oxon Hill, MD. We look forward to seeing you!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-29.70M -	-241.34M 712.48%	-245.39M 1.68%	-548.98M 123.72%	-175.77M 67.98%
depreciation and amortization	6.41M -	11.73M 83.14%	21.81M 85.84%	59.31M 171.97%	35.83M 39.58%
deferred income tax			-195.97M -	-49.12M 74.93%	-926K 98.11%
stock based compensation	5.48M -	120.23M 2,093.20%	219.42M 82.50%	41.98M 80.87%	-326K 100.78%
change in working capital	-737K -	13.85M 1,978.83%	8.08M 41.66%	36.13M 347.28%	-38.24M 205.84%
accounts receivables	-4.57M -	-10.61M 132.34%	5.54M 152.16%	5.53M 0.14%	10.26M 85.69%
inventory	-7.97M -	-8.98M 12.66%	-10.62M 18.32%	4.60M 143.30%	975K 78.80%
accounts payables	10.38M -	34.44M 231.87%	13.04M 62.12%	34.46M 164.18%	-46.95M 236.26%
other working capital	1.42M -	-1.00M 170.34%	123K 112.29%	-8.46M 6,973.98%	-2.53M 70.12%
other non cash items	-176K -	2.40M 1,463.64%	1.62M 32.46%	141.53M 8,631.28%	-721K 100.51%
net cash provided by operating activities	-18.73M -	-93.13M 397.27%	-190.43M 104.49%	-319.15M 67.59%	-180.15M 43.56%
investments in property plant and equipment	-15.46M -	-31.97M 106.87%	-20.79M 34.99%	-14.32M 31.10%	-5.71M 60.12%
acquisitions net				-127.00M -	-8.11M 93.61%
purchases of investments					-47.67M -
sales maturities of investments					17.77M -
other investing activites					-1 -
net cash used for investing activites	-15.46M -	-31.97M 106.87%	-20.79M 34.99%	-141.33M 579.91%	-43.73M 69.06%
debt repayment	-1.71M -	-4.20M 145.52%	-13.47M 221.00%	-3.29M 75.56%	-42.95M 1,204.71%
common stock issued		117.32M -	442.68M 277.32%	200.61M 54.68%	143.29M 28.57%
common stock repurchased
dividends paid
other financing activites	149.72M -	15.93M 89.36%	64.51M 305.04%		85.90M -
net cash used provided by financing activities	148.01M -	129.06M 12.81%	493.73M 282.57%	197.31M 60.04%	186.24M 5.61%
effect of forex changes on cash					-87K -
net change in cash	113.83M -	3.95M 96.53%	282.51M 7,044.89%	-263.17M 193.15%	-37.72M 85.67%
cash at beginning of period	1.18M -	115.01M 9,662.82%	118.96M 3.44%	401.47M 237.48%	137.40M 65.77%
cash at end of period	115.01M -	118.96M 3.44%	401.47M 237.48%	138.30M 65.55%	99.68M 27.93%
operating cash flow	-18.73M -	-93.13M 397.27%	-190.43M 104.49%	-319.15M 67.59%	-180.15M 43.56%
capital expenditure	-15.46M -	-31.97M 106.87%	-20.79M 34.99%	-14.32M 31.10%	-5.71M 60.12%
free cash flow	-34.18M -	-125.10M 265.97%	-211.22M 68.84%	-333.48M 57.88%	-185.86M 44.27%

COM:GENEDX

GeneDx Holdings Corp.

Last Close

72.07

22/11 21:00

Market Cap

2.16B

Beta: -

Volume Today

549.30K

Avg: -

Preview